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27.1 INTRODUCTION
Adverse drug reactions involving the skin are a common 
problem but their real incidence is not known. Among inpa-
tients 2–5% experience a cutaneous adverse drug reaction 
(CADR)1,2 but, although it is a frequent cause of consultation 
or urgent observation at a Dermatology department,3 no pre-
cise data exists concerning its incidence in outpatients. Only 
2% are severe reactions,1 therefore, most are not reported 
to the pharmacovigilance systems. Also, in some cases, the 
diagnosis of CADR is one of presumption, with no defi nitive 
test to prove it, or of exclusion for which the dermatologist has 
to be alert. Some CADR are mild and resolve spontaneously, 
others represent an exaggeration of the drug pharmacologi-
cal effect, some are similar to viral exanthems or idiopatic 
urticaria, and others mimic skin diseases which are not usu-
ally drug-induced, namely pemphigus, bullous pemphigoid, 
lupus erythematosus, psoriasis, and lichen plannus.1,3,4 
27.2  PATHOMECHANISMS IN CUTANEOUS 
ADVERSE DRUG REACTIONS
27.2.1  IMMUNE AND NONIMMUNE MECHANISMS 
INVOLVED IN CADR
Most CADR are certainly not immune mediated, represent-
ing a pharmacological drug effect often exaggerated due to 
drug interactions, concomitant diseases that modify drug 
bioavailability, or predisposing genetic polymorphisms of 
drug detoxifying enzymes. As an example, skin and oral 
mucosa erosions can occur during metothrexate treatment 
in patients with low serum albumin, low renal clearance, or 
on concomitant use of nonsteroidal antiinfl ammatory drugs 
(NSAID). These predictable reactions, called type A, may 
represent up to 80% of CADR4 and are not the object of this 
chapter. 
Unpredictable, idiosyncratic CADR, called type B, 
namely drug “rashes” or “drug eruptions,” are those mostly 
dependent on immune hypersensitivity reactions. CADR 
upon systemic drug exposure include a wide variety of skin 
reaction patterns occurring either immediately upon expo-
sure or with a delay of hours, days, sometimes after weeks, 
or months of drug administration, depending on the hyper-
sensitivity mechanisms involved and whether the individual 
is already sensitized or not. The pathogenic mechanisms 
involved are not usually simple and include a complex inter-
play of different effectors of the immune system, which 
orchestrate the immuno-infl ammatory skin reaction in a still 
not yet fully understood way.1,4 
The 4 classical mechanisms of immune hypersensitivity 
defi ned by Gell and Coombs participate in CADR. Immedi-
ate type I hypersensitivity from drug specifi c IgE is involved 
in acute urticaria and anaphylaxis, type II antibody-mediated 
cytotoxicity is reported in drug-induced hemolytic anemia 
and drug-induced immune complexes can be deposited in 
small cutaneous vessels inducing leukocytoclastic vasculitis, 
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representing a type III reaction.4 Delayed type IV hypersen-
sitivity involving T cells that specifi cally recognize the drug 
(or a drug metabolite) has been well documented namely in 
generalized maculopapular exanthema (MPE), in the drug 
induced hypersensitivity syndrome (DIHS) also known as 
DRESS (Drug-induced rash with eosinophilia and systemic 
symptoms), in acute generalized exanthematic pustulosis 
(AGEP), in fi xed drug eruption (FDE), and in the more wide-
spread and severe Stevens–Johnson syndrome (SJS) or toxic 
epidermal necrolysis (TEN).4–6 For each of these different 
clinical and histological patterns, delayed hypersensitivity 
is involved through different subsets of T cells and soluble 
effectors that recruit a wide range of other cells and orches-
trate the infl ammatory response, inducing lesions that affect 
only the skin or, eventually, also other organs.5
Topical drugs cause allergic contact dermatitis, a typi-
cal T-cell mediated reaction, which can become widespread 
simulating a drug eruption due to percutaneous drug absorp-
tion.6,7 Also, systemic exposure to drugs to which patients 
were previously sensitized through the skin can induce 
systemic contact dermatitis,8 presenting as a “baboon syn-
drome” also known as SDRIFE (symmetrical drug-related 
intertriginous and fl exural exanthema)9 or an acrovesicular 
dermatitis.6,8
Photo-active drugs, either upon topical or systemic expo-
sure, can induce a photosensitive eruption on sun exposed 
areas, due to a phototoxic or a photoallergic mechanism, in 
this case dependent on a type IV hypersensitivity reaction to 
the drug or a photoproduct. One such example is piroxicam, a 
NSAID which upon UVA exposure gives rise to a photoprod-
uct chemically and antigenically similar to the thiosalicylate 
moiety of thiomersal, and, therefore, induces photoallergy in 
individuals previously sensitized to thiomersal.10,11
In some cases, the drug modifi es the immune response 
promoting autoimmunity or induces the production of patho-
genic antibodies directed against skin structures, as in van-
comycin-induced linear IgA dermatitis,12 in drug-induced 
pemphigus, and in terbinafi ne-induced subacute lupus ery-
thematosus. Sometimes autoantibodies are found during the 
eruption but their pathogenic signifi cance is not known, as in 
a case of DRESS with antibodies against the 190 kDa antigen 
targeted usually in pemphigus foliaceus or paraneoplastic 
pemphigus.13
27.2.2  DRUG RECOGNITION BY THE IMMUNE 
SYSTEM AND SKIN REACTION PATTERNS
Apart from the wide list of drugs capable of inducing immune 
mediated CADR, each drug can induce several skin reaction 
patterns and depending on the reaction pattern (and some-
times within the same reaction pattern), the antigenic moiety 
recognized by the immune system is different: the drug itself, 
an intermediate metabolite, both the drug and a metabolite, 
or proteins/peptides modifi ed by reactive drugs or metabo-
lites. Drugs can be specifi cally recognized by IgE in imme-
diate hypersensitivity, by antibodies fi xed on red blood cells 
inducing hemolytic anemia, by soluble antibodies inducing 
immune complex vasculitis, or by the TCR of T cells, both 
in the context of HLA-class I or class-II molecules and either 
covalently or noncovalently bound.14,15 The problem is more 
complex as, for instance, in the case of MPE from cotri-
moxazol, some T-cell clones recognize sulfamethoxazole 
and other antiinfectious sulfonamides with a same confor-
mational structure, giving rise to cross-reactions,16 whereas 
other T-cell clones recognize intermediate metabolites, like 
hidroxilamine sulfamethoxazole or nitroso sulfamethoxa-
zole,15 either presented directly in the HLA groove14,15 or 
after antigen processing and with MHC restriction,14,16 with a 
more restricted cross-reactive pattern. In the case of immedi-
ate hypersensitivity to penicillin, IgE can recognize either 
the benzylpenicilloyl moiety or the side chain; therefore, rec-
ognizing by cross-reaction other penicillins or, eventually, 
also cephalosporins.17,18 For piroxicam, the moiety recog-
nized by the immune system depends on the reaction pat-
tern. The thiosalicylate moiety, which is formed after UVA 
radiation is responsible for the photoallergic reaction. As this 
photoproduct is exclusive for piroxicam, other oxicams like 
tenoxicam can be safely used in photoallergy. Whereas, in 
FDE the immune system recognizes another oxicam moiety 
which is common to tenoxicam and, therefore, all patients 
with FDE to piroxicam cross react with tenoxicam.10,11,19
27.2.3  CONCOMITANT AND PREDISPOSING 
FACTORS IN DRUG ERUPTIONS
Even though we do not understand all the steps of sensitiza-
tion to drugs and how some individuals become sensitized 
and develop CADR while others do not, there are few known 
predisposing factors. 
One important aspect deals with the drug detoxifi cation 
process where polymorphisms within drug metabolizing 
enzyme genes, namely in the cytochrome P450, can give rise to 
different intermediate reactive (or nonreactive) drug metab-
olites or to distinct amounts of the culprit metabolite.20,21 
Some HLA haplotypes, which may be related to the capac-
ity of the drug to combine or insert into the HLA groove of 
antigen presenting or target cells, have been associated with 
increased or reduced capacity to develop a drug eruption to 
a certain drug,5 as shown for HLA-B*1502 predominance in 
patients from Twaian who develop SJS to carbamazepine.22 
Also polymorphisms in immuno-infl ammatory response 
pathways may increase the risk of some particular drug reac-
tions: predisposition to produce higher levels of soluble FAS 
ligand and polymorphisms in the TNF-promoter region may 
correlate with an increased severity of drug reactions,5,22 
disturbances in complement and cinin metabolism, namely 
in carboxypeptidase that degrades bradykinin, may favor 
angioedema induced by ACEI, and polymorphisms in the 
gene for LTC4 synthase may justify familial aggregation of 
aspirin induced urticaria.23
Also, the immune status of the patient during drug expo-
sure may be important for the outcome of the CADR. Con-
comitant aggressions (exposure to other reactive chemicals or 
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chronic immuno-infl ammatory diseases (Still’s disease, sys-
temic lupus erythematosus), or nonspecifi c immune activa-
tion by reactive drug metabolites may act as “danger” signals 
that alert the innate immune system and activate monocyte/
macrophages or dendritic cells that become increasingly 
capable of presenting the drug to T cells.20,24 Therefore, these 
concurrent factors may be of extreme importance, especially 
during active drug sensitization, but also during the develop-
ment of the CADR in a sensitized individual. As an exam-
ple, patients with systemic lupus erythematosus or HIV+ 
patients are more susceptible to CADR, namely from sulfon-
amides.15,24 During Epstein-Barr virus (EBV) or Cytomega-
lovirus (CMV) infection, antibiotics induce MPE in a high 
proportion of patients,25,26 but even though aminopenicillins 
induce an MPE in almost every patient, only a few of these 
really become sensitized to the drug and develop a skin rash 
on re-exposure without the concomitant infection.25–27 Also, 
during the last decades attention has been drawn to the asso-
ciation of the DIHS/DRESS with human herpes virus type 6 
(HHV-6) primo-infection or reactivation.26,28,29 Concomitant 
use of aminopenicillins and allopurinol also seem to repre-
sent a risk factor for developing CADR.25,30
Nevertheless, and apart from these diffi culties and vari-
ables that complicate, the study of pathomechanisms involved 
in CADR, immediate and delayed skin testing, drug rechal-
lenge, and in vitro studies using drug specifi c antibodies or 
drug specifi c T cell clones isolated from the blood and skin of 
patients with CADR or from positive skin tests, have brought 
new light into the immune mechanisms involved in CADR, 
that we will review for the main reaction patterns.
27.3 IMMEDIATE ADVERSE DRUG REACTIONS
These reactions occur within minutes to a few hours after 
drug exposure and present clinically as pruritus, urticaria, or 
angioedema regressing with no residual lesions within min-
utes to hours. In severe cases, urticaria and angioedema are 
associated with systemic symptoms like nausea, abdominal 
cramps, sneezing, bronchospasm, and dispnea that can prog-
ress to hypotension and shock in its most severe expression—
anaphylaxis. The most severe acute immediate reactions are 
induced by beta-lactam antibiotics (pencillin G and amino-
penicillins), iodinated radiocontrast media, and muscle relax-
ants used in anesthesia, whereas the more frequent but less 
severe immediate reactions are due to aspirin and NSAID, 
codein, vancomycin, angiotensin conversing enzyme inhibi-
tors (ACEI), heparins, and insulin, but any drug can induce 
an immediate adverse reaction.4,17,31 (Figure 27.1 showing an 
immediate reaction with urticaria and angioedema from a 
NSAID.)
Immediate reactions are dependent on drug specifi c 
IgE fi xed on tissue mast cells and circulating basophils, but 
clinically similar reactions, although usually less severe, 
occur without the identifi cation of a drug specifi c immune 
reaction, and are, therefore, called pseudoallergic or ana-
phylactoid.1,4,31 In all cases, the tissue mast cells, blood 
basophils and, eventually, platelets,32 liberate the content of 
their granules (histamine, tryptase, heparin, cytokines, and 
chemokines) and produce secondary vasoactive mediators 
(prostaglandins, leukotrienes, PAF/platelet activation factor, 
and cinins), which together are responsible for the vasodilata-
tion, increased vascular permeability, and pruritus observed 
in urticaria.4,33 
In immediate hypersensitivity, cell degranulation occurs 
upon specifi c mast cell or basophil IgE bridging by the drug.4 
Nevertheless, degranulation can occur by nonIgE dependent 
mechanisms like the activation of cell receptors for comple-
ment anaphylotoxins (C3a and C5a), direct drug effect on 
the cellular membrane or in intracellular pathways that regu-
late degranulation, or imbalance between prostagladins and 
leukotrienes due to cyclooxygenase inhibition by NSAID. 
Still, a similar reaction can occur from the increase of bradi-
kinin and other vasoactive mediators due to drugs that inhibit 
their degradation, like ACEI.1,4,34–36
In immediate hypersensitivity reactions, a drug specifi c 
IgE is found in in vitro tests, there is in vitro drug specifi c 
basophil activation (measured either by the expression of 
CD63 by fl ow cytometry or by mediator release),33,37 and 
immediate skin testing (prick or intradermal) and drug 
rechallenge (which is not advised in severe cases) are posi-
tive in a high proportion of patients (>80%).31 Nevertheless, 
with several drugs that induce IgE mediated reactions, like 
muscle relaxants, iodinated radiocontrast media and hepa-
rins, there is also a direct capacity for nonspecifi c basophil or 
mast cell activation, which can be responsible for nonspecifi c 
FIGURE 27.1 Angioedema and urticarial lesions after ingestion 
of a NSAID (diclofenac).
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positive skin and basophil activation tests (CD63 expression 
or mediator release).34,35,38 Also, occasionally, drug specifi c 
IgE has been documented in aspirin-induced urticaria and 
asthma, classically considered pseudoallergic,39 and even 
for penicillin a nonspecifi c capacity for mast cell activation 
(albeit low) has been documented in vitro. Therefore, this 
makes the distinction between what are called allergic and 
pseudoallergic reactions diffi cult, both on clinical and labo-
ratory grounds. 
Drug specifi c IgG or IgM antibodies can also be responsi-
ble for immediate symptoms,36 because these antibodies give 
rise to circulating immune complexes and complement acti-
vation and induce urticaria with systemic symptoms within 
the context of serum disease (fever, arthralgia or arthritis, 
abdominal pain and urticaria, urticaria vascultis, or leuko-
cytoclastic vasculitis), which occurs either immediately or 
within a few days of drug administration.4,40
27.4  DELAYED CUTANEOUS ADVERSE 
DRUG REACTIONS
There are several clinical and experimental arguments that 
confi rm the involvement of delayed type hypersensitivity 
with the participation of drug specifi c T cells in the follow-
ing CADR: MPE, DIHS/ DRESS, AGEP, SJS, TEN, and 
FDE.4,24,41 (1) These eruptions begin within 7–21 days in 
the 1st episode and 1–2 days after drug reintroduction; (2) 
Drug specifi c positive oral rechallenge with lower doses is 
usually observed;42 (3) On histopathology there is mainly a 
dermo-epidemal infi ltration of activated T cells; (4) In a high 
percentage of cases, the culprit drug induces specifi c posi-
tive patch, prick, or intradermal skin testing with delayed 
readings;6,43–46 (5) In vitro tests show drug specifi c T lym-
phocyte proliferation/activation;47,48 and (6) Drug specifi c 
T-cells lines and T-cell clones have been isolated from the 
blood and skin during the acute episode or, later, from posi-
tive patch tests.41,49
Nevertheless, as there are distinct subsets of T cells with 
distinct cytokines/chemokines and aggressive machinery, 
they orchestrate the infl ammatory skin reaction giving rise to 
different patterns of drug reactions. Therefore, a subdivision 
of delayed hypersensitivity T-cell reactions has been made in 
agreement into type IVa, IVb, IVc and, more recently, type 
IVd.5 They represent, respectively, the reactions medi-
ated predominantly by T-helper 1 (interferon (IFN)-γ), 
T-helper 2 (interleukin (IL)-4 and IL-5), cytotoxic reactions 
(CTL, CD8+ rich in perforin, granzyme B, and FasL), and 
CXCL8 (IL-8) secreting T cells that promote neutrophilic 
infl ammation.24,50 
The participation of these subsets is very particular in 
the different patterns of delayed drug eruptions, as detailed 
below in Table 27.1.
27.4.1 MACULOPAPULAR EXANTHEMS
MPE, the most frequent pattern of CADR, appear as gen-
eralized symmetric eruptions of isolated and confl uent ery-
thematous macules or papules, often starting in the trunk and 
then spreading to the extremities. Mucosa are not involved, 
there are no evident systemic symptoms apart from a low-
TABLE 27.1
General Aspects of the Hypersensitivity (HS) Mechanisms Involved in the Main CADR
Type of Reaction Immediate Delayed
Reaction pattern Urticaria/
anaphylaxis
MPE DRESS AGEP SJS/TEN FDE
Main drugs Penicillins, Antibiotics Anticonvulsivants Antibiotics Allopurinol NSAID
Contrast media, Anticonvulsivants Allopurinol Aminopenicillins Anticonvulsivants
NSAID Allopurinol Minocycline Sulfonamides
Drug recognition IgE TCR/HLA I-II TCR/HLA-II TCR /HLA I TCR TCR
Effector cells Mast cells CD4/CD8 CD4/CD8 CD4+ CD8+CD56+ CD8+CD69
Basophils eosinophils neutrophils
Soluble mediators Histamine Perforin IL-5 CXCL8 Fas/FasL Fas/FasL 
Tryptase IFN-γ IFN-γ GM-CSF TNF-α IFN-γ
PGs, LTs, PAF IL-5 IFN-γ Perforin





In vivo tests Prick/idr Patch testing oral 
challenge
Patch testing Patch testing … Lesional testing
Oral challenge
In vitro tests Specifi c IgE LTT LTT LTT LTT N/A
Basophil activation
Other aspects Similar to 
pseudoallergic 
reactions
Mimic viral and 
bacterial 
exanthems
Concomitant Neutrophilic High mortality rate “preactivated” T cells
in residual lesions HHV-6 Infl ammation
Type of HS Type I Type IVa, IVb, and 
IVc
Type IVa, IVb, and 
IVc
Type IVd Type IVc Type IVc
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grade fever which can also contribute to mimic a viral or 
bacterial exanthem. The reaction develops within 7–14 days 
after drug intake (or within 1 or 2 days in sensitized patients) 
mainly due to antibiotics (aminopenicillins, cefalosporins, 
and sulfonamides), allopurinol, and anticonvulsivants. 
The reaction may be mild and regress within a few days, 
but most often it progresses for a few days even after drug 
suspension and then fades progressively within 10–15 days, 
often with desquamation.5,51 (Figure 27.2 showing a MPE 
from carbamazepine.)
On histopathology, early lesions show an interface derma-
titis with hydropic degeneration of basal keratinocytes, mild 
spongiosis, scattered dyskeratotic and necrotic keratinocytes, 
and lymphocytes mainly at the dermal epidermal junction and 
in papillary dermis with eosinophils along dermal vessels.51,52,24 
Lymphocytes are skin homing highly activated T cells (CLA+, 
CD3+, DR+, CD25+) expressing adhesion molecules such 
as CD11a-CD18 (LFA-1) and CD62L (L-selectin). They 
are attracted from the blood through the expression of the 
corresponding adhesion molecules in endothelial cells and 
keratinocytes (ICAM-1, HLA-II) and by the production of 
keratinocyte chemokines, like the CCRL27 (also known as 
CTACK-cutaneous T-cell attracting chemokine) that selec-
tively recruits skin homing memory T cells expressing the 
CCR10 receptor.15,52,53 Most lymphocytes infi ltrating the 
skin are CD4+ T cells expressing high levels of perforin 
and granzyme B but CD8+ T cells are also found, mainly in 
the epidermis.5,51,52 T cells secrete an heterogenous profi le of 
cytokines and chemokines: type 1 cytokines (IFN-γ) activate 
dendritic cells and keratinocytes increasing their expression 
of HLA-II that binds the drug and presents it to T cells; IL-5, 
a type 2 cytokine, along with the eotaxin/CCL-11 is respon-
sible for the recruitment and activation of eosinophils, a local 
and systemic hallmark of cutaneous maculopapular drug 
eruptions.51 During the acute phase, CLA+CD4+ T cells 
expressing perforin are also increased in the blood and after 
isolation exhibit in vitro cytotoxic activity against keratino-
cytes, therefore, reinforcing their capacity to cause keratino-
cyte damage in the skin.51 Similar cells have been isolated 
from positive epicutaneous patch tests with the culprit drug 
and it has been shown that the T-cell clones isolated from the 
blood, skin, and positive patch tests in patients with MPE are 
specifi cally stimulated by the culprit drug and exhibit similar 
profi les of activity, namely perforin expression and produc-
tion of cytokines and chemokines (INF-γ, IL-5).41,49
Therefore, after a process of T-cell sensitization, a further 
exposure to the drug that reaches the skin and combines with 
skin proteins or HLA molecules of keratinocytes and den-
dritic cells, activates resident skin and circulating CD4+ and 
CD8+ T cells, which are attracted to the skin and selectively 
damage the cells where the drug is fi xed, mainly by perfo-
rin and granzyme B. Cytokines and chemokines produced 
by T cells and resident skin cells recruit other infl ammatory 
cells that orchestrate the dermal and epidermal infl amma-
tory reaction in MPE. Therefore, various subtypes of delayed 
hypersensitivity, mainly type IVa, Ivb, and IVc seem to be 
involved in this pattern of CADR.5
27.4.2  DRUG-INDUCED HYPERSENSITIVITY 
SYNDROME/DRUG REACTION WITH 
EOSINOPHILIA AND SYSTEMIC SYMPTOMS
DRESS is a severe life-threatening CADR that develops 2–8 
weeks after drug intake, usually an anticonvulsivant, allo-
purinol, a sulfonamide, dapsone, or minocycline. It involves 
the skin, presenting with a nonspecifi c maculopapular rash or 
a more generalized exfoliative dermatitis, often with severe 
facial edema (Figure 27.3 shows a case of DRESS induced by 
allopurinol with an exfoliative dermatitis and facial edema). 
Systemic symptoms are always present and consist of fever, 
malaise, arthralgia, enlarged lymph nodes, hepatic, renal or 
pulmonary failure, and blood leukocytosis with circulating 
atypical (activated) lymphocytes and eosinophilia that some-
times occurs a few days later. It begins after a longer interval 
than for other drug rashes and also regresses slowly often with 
exacerbations, either related with steroid withdrawal, viral 
reactivation, or administration of a cross reactive drug.1,28,29 
Also, delayed reactivation apparently with no drug exposure 
or with exposure to a nonrelated drug have been reported.54
In DRESS, circulating activated T cells expressing 
CLA+ and CCR10 increase in the blood in proportion with 
the skin severity, and these CD4+ and CD8+ T cells infi l-
trate the dermis and epidermis.15 In carbamazepine and 
lamotrigine sensitive patients, T-cell clones generated from 
these infi ltrating skin and circulating cells, react specifi cally 
to these drugs on HLA-II matched antigen presenting cells 
FIGURE 27.2 Maculopapular exanthem from carbamazepine.
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apparently independent of drug metabolism and antigen pro-
cessing.15 These T cells have a αβ TCR, almost all with the 
Vβ 5.1 chain, suggesting that the drug might also act as a 
superantigen.55 These T-cell clones are rich in perforin and 
secrete a type 1 cytokine pattern with IFN-γ and chemokines 
that control the duration and severity of the infl ammatory 
response,15 but they also show a very signifi cant IL-5 secre-
tion which is responsible for the characteristic eosinophilia 
observed in this syndrome.56 
Nevertheless, and even though these drug specifi c T-cells 
clones have been isolated in DRESS15 and, in our experience, 
patch tests with the drug, namely with carbamazepine, are 
often positive,57 the pathomechanisms involved seem to be 
complex and not exclusively dependent on the drug. Most 
authors refer the need for a concomitant HHV-6 reactivation, 
which would be responsible for the systemic symptoms as 
well as for exanthem reactivation without drug.29,28,54 Recent 
studies presented by Yoko Kano and Testsuo Shiohara sug-
gest that HHV-6 reactivation, evaluated by detection of viral 
deoxyribonucleic acid (DNA) by Polymerase chain reaction 
(PCR) and by the increase in anti-HHV-6 IgG titer in blood, 
occurs after a certain degree of immunossupression, particu-
larly hypogammaglobulinemia, induced by the drug.29 They 
also suggest that, just after drug suspension, the recovery of 
CD4+ and CD8+ cells will be responsible for an immune 
reconstitution infl ammatory syndrome (IRIS) with damage 
of the tissues where the virus/drug is localized, as observed 
in acquired immune defi ciency syndrome (AIDS) after 
highly active antiretroviral therapy (HAART) treatment.58 
This might explain why, in their experience, lymphocyte 
transformation tests (LTT) are positive only after a certain 
time of evolution of the DRESS when there is a full immune 
reconstitution.58
Although drug specifi c T cells with a high production 
of IL-5 and eotaxin, responsible for the systemic and skin 
eosinophilia,55,56 have been observed in DRESS, suggest-
ing the involvement of a type IVb and IVc hypersensitivity 
reaction, further studies are needed to fully understand the 
mechanisms underlying this severe ADR.
27.4.3 ACUTE EXANTHEMATIC GENERALIZED PUSTULOSIS
AGEP is a very peculiar reaction pattern induced by drugs 
in more then 90% of cases, mainly by aminopenicillins and 
other antibiotics. It is characterized by the acute onset of 
symmetrical widespread edematous erythema covered by 
small nonfollicular sterile pustules, predominating in the 
face and body folds, high fever (>38°C), leukocytosis, neu-
trophilia and, occasionally, eosinophilia. (Figures 27.4a and 
27.4b show a patient with AGEP from amoxicillin with the 
predominance of small pustules on body folds.) The reac-
tion develops around 1 week after drug intake and regresses 
in 5–10 days after drug withdrawal. Lymphocyte transfor-
mation tests and, typically, patch tests are positive9 and, 
after 72 hours, show a pustulous pattern similar to the acute 
reaction.60,61
The histology and immunohistochemistry of early 
biopsies from AGEP show a dermo-epidermal infi ltration 
of T cells, mainly CD4+DR+CD25+, with discrete vacu-
olar keratinocyte degeneration and a perivascular infi ltrate, 
sometimes with vasculitis.62,63 Lesions progress to spongiotic 
vesicles that soon transform into subcorneal pustules due to 
neutrophil accumulation.63 This same pattern occurs at posi-
tive patch tests, which make them a very useful tool to study 
the pathomechanisms involved in AGEP. From the blood and 
skin biopsies of patch tests, several drug-specifi c T-cell lines 
and T-cell clones have been isolated and characterized. They 
are mainly CD4+ memory effector T cells, which exhibit 
cytotoxicity against drug laden target cells, both through 
perforin/granzyme B and Fas ligand.64 They secrete mainly 
a type 1 cytokine pattern (IFN-γ and GM-CSF), in some 
cases with IL-5, responsible for eosinophilia observed in 
about one third of AGEP patients.61 Nevertheless, the main 
particular characteristic of these T cells is the high produc-
tion of CXCL8 (IL-8) and other cytokines, like GM-CSF, 
that recruit and prolong survival of neutrophils in the skin. 
Actually, in vitro tests have shown that apart from CXCL8 
that recruits neutrophils bearing the CXCR1, other media-
tors of these T cells, like GM-CSF and INF-γ, acting mainly 
through the CXCR2, prevent neutrophil apoptosis and pro-
long their skin survival.60
But, preceding neutrophil skin infi ltration, drug specifi c 
CD4+ T cells (with less than 30% CD8+), expressing CCR6 
as the skin homing receptor, are present in the skin and 
exert some cytotoxicity in the epidermis5 before they secrete 
FIGURE 27.3 Exfoliative dermatitis with facial edema in a case 
of DRESS induced by allopurinol.
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CXCL8 that recruits neutrophils. As both T cells and kerati-
nocytes secret CXCL8 and T cells also express the CXCR1, 
there is further T-cell activation by CXCL8 produced by kera-
tinocytes.61 Opposing MPE, there is a much lower expression 
of HLA-II by keratinocytes and no exotaxin was observed in 
the epidermis, but only along endothelial cells.61
This very peculiar pattern of drug specifi c T-cell reaction, 
now considered a type IVd hypersensitivity reaction,5 devel-
ops with drugs that usually induce other type IV reactions, 
namely aminopenicillins. No reason has, thus far, been found 
to justify why in some patients and in what circumstances a 
drug can elicit this particularly CXCL8 rich Tcell activity. 
27.4.4  STEVENS–JOHNSON SYNDROME/
TOXIC EPIDERMAL NECROLYSIS
SJS and its more extensive variant, TEN, represent a life-
threatening pattern of CADR characterized by widespread 
symmetrically distributed macular lesions, showing typical 
or mainly atypical targets, with central bulla, that coalesce 
to form large sheets of necrotic epidermis covering more 
than 30% of the body surface area in TEN (Figure 27.5 rep-
resent a case of TEN from allopurinol, with skin detach-
ment involving about 60% of the body surface area). The 
eruption is often preceded by fever, malaise, mucosal pain/ 
erosions and, as the skin rash progresses from the head to 
the extremities, fever and systemic symptoms occur in a 
variable intensity and combination. Conjunctivae, oral, and 
genital epithelial shedding is usually intense and painful, 
and can be associated with epithelial necrosis of the oro-
pharynx, gastrointestinal tract, trachea, and bronchia. SJS/
TEN are due to drugs in more than 90% of cases, usually 
an antibiotic (sulfonamide), allopurinol, an anticonvulsivant 
(lamotrigine, carbamazepine), or a NSAID (oxicam).1,4 In 
the skin there is a variable degree of infl ammatory infi ltrate, 
ranging from almost absent to a dense dermal T infi ltrate, 
which seems to correlate positively with the percentage of 
the area of skin detachment and, consequently, with the 
mortality rate.65,66 Factor XIIIa+ dermal dendritic cells are 
increased contrasting with a reduction of CD1a+ Langer-
hans cells. CD4+ and CD8+ T cells are scattered in the 
dermis and many cytotoxic activated CD8+CD56+ T cells 
are found in the blister fl uid.67,68 But the most striking histo-
logic marker of TEN is the keratinocyte cell death extending 
to all epidermal layers.65 There is evidence that this is due to 
apoptosis, dependent on several mechanisms. The Fas/Fas 
ligand (CD95/CD95L) pathway, in its membrane bound or 
soluble form, seems to be mainly involved, but there are 
other pathways leading to keratinocyte apoptosis, namely 
TNF-α, granzyme B, and perforin and calcium dependent 
calprotectin.69–71 These soluble mediators are found in high 
amounts in the serum but very particularly in the blister 
fl uid, where they are detected with other cytokines that may 
be liberated by damaged keratinocytes and which amplify 
the infl ammatory loop and the epidermal apoptosis, namely 
IL-18, IFN-γ, and IL-10.71 
FIGURE 27.5 Extensive skin detachment in a patient with toxic 
epidermal necrolysis from allopurinol.
FIGURE 27.4 (a) Acute generalized exanthematic pusutulosis 
induced by amoxycillin. (b) Detail of Figure 27.4a. Small pustules 
mainly on body folds in AGEP.
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The main origin of these death mediators are drug spe-
cifi c T cells, mainly CD8+, present in the blister fl uid of 
patients with TEN.67,68 These CD8+CD56+ T cells have 
an important cytotoxic potential against HLA-I restricted 
keratinocytes combined with the culprit drug, mainly due to 
granzyme B and perforin,16,68 but also through soluble FAS 
produced in high amounts after drug stimulation of these 
cells.70 Therefore, after a fi rst aggression by CD8+ cyto-
toxic T cells that need cell contact or proximity, other soluble 
mediators secreted by drug specifi c T cells (IFN-γ, sFAS) can 
be important for disease spreading. IFN-γ activates keratino-
cytes that increase HLA-I expression, rendering them more 
susceptible to CD8+ specifi c T-cell killing,16 upregulates 
their secretion of CCL27/CTACK, a potent chemokine that 
further attracts CCR10+ cutaneous memory T cells,53 and 
increases their expression of receptors for TNF and Fas and 
their production of Fas ligand, making keratinocytes more 
susceptible to apoptosis and capable of inducing apoptosis of 
neighboring cells.16
The factors that drive the CADR into a SJS or TEN are 
not known. TEN inducing drugs are not different from those 
that induce other CADR, and sometimes at the beginning 
the skin reaction simulates a MPE. Nevertheless, increased 
serum levels of soluble Fas may indicate the progression to 
a more severe life-threatening reaction,70 and some authors 
suggest that, in individuals who develop SJS or TEN, their 
lymphocytes have an increased capacity of secreting sFas, 
even in basal conditions.22 Therefore, this and other genetic 
susceptibility markers can be of importance in determining 
this pattern of CADR.
27.4.5 FIXED DRUG ERUPTION
FDE is due to drug hypersensitivity in more then 95% of the 
cases. The clinical presentation is very typical, with round 
erythematous lesions, that may progress to plaques or bulla 
and regress spontaneously within 10–15 days with a grey-
brown hyperpigmentation (Figure 27.6 shows two typical 
round lesions of FDE induced by piroxicam). Lesions may 
vary from a few to a widespread involvement making a dif-
ferential diagnosis with TEN diffi cult.19,72
At the acute phase there is a mononuclear infl amma-
tory infi ltrate, mainly at the dermal epidermal junction, with 
hydropic degeneration of basal keratinocytes and scattered 
or more extensive apoptosis of keratinocytes, eventually 
involving the whole epidermal thickness, as in TEN. Upon 
regression, melanophages are easily visible in the dermis for 
years and, if special immunohistochemical stains are per-
formed, CD8+ T cells can also be detected in the epidermis 
in abnormal numbers over prolonged periods after clinical 
resolution,74 probably due to the expression of the skin hom-
ing receptor (CLA+) and the integrin α3β7 (CD103), which 
binds E-cadherin in keratinocytes.73,75 They are CD3+, 
CD45RA+, CD11b+, and CD8+ effector memory T cells 
that share some surface and activation markers with NK cells, 
namely the CD69,73,75 but they do not harm the neighboring 
cells, which are protected from apoptosis.74 Within a few 
hours upon exposure to the culprit drug these resting or “pre-
activated” T cells initiate a process of epidermal aggression. 
They upregulate mRNA for IFN-γ and secrete this cytokine 
in high amounts;73,74 they express FAS-ligand which binds 
FAS on keratinocytes, thus, inducing apoptosis;73–75 TNF-
alfa, perforin, and granzyme secreted by these cells and 
other CD8+ effector T cells recruited from the circulation 
also participate in the epidermal aggression.73,74  Along with 
CD8+, which migrate mainly to the epidermis and CD4+ 
which localize preferentially in the dermis and among this 
subgroup, CD4+CD25+hi regulatory T cells seem to down-
regulate the reaction either by direct cell contact or by secre-
tion of IL-10 or TGF-β.76 These cells also seem to be involved 
in the process of desensitization in FDE.77
The presence of the “pre-activated” T cells in the resid-
ual lesional epidermis can explain why patch testing is nega-
tive in normal skin whereas, a few hours after application 
of the culprit drug in a residual lesion reactivation occurs 
with the clinical and histhopathology typical of a FDE.19,72 
Although some authors suggest that these lesions can be 
reactivated by nonspecifi c stress/danger signals,74,78 in our 
experience lesional reactivation by patch testing is drug 
specifi c and allows the confi rmation of the culprit drug and 
study of cross reactions.19,79 
27.5 CONCLUDING REMARKS
The knowledge of the pathomechanisms involved in drug 
hypersensitivity are of extreme importance for the clinician 
to understand the clinical and evolutive pattern of CADR, 
to choose the most adequate therapeutic attitude when fac-
ing a CADR, to understand and determine which drug is 
imputed with the highest probability in patients on multiple 
therapies, to further choose the most adequate complemen-
tary tools to confi rm the culprit drug (immediate skin tests 
and IgE/basophil activation tests in immediate reactions, 
patch testing, or IDR with late readings and LTT in delayed 
reactions), and to take the most adequate preventive mea-
sures to avoid a further CADR. 
Nevertheless several aspects of these mechanisms are not 
yet fully understood, namely what triggers sensitization to 
the drug, which drug epitopes (or other related epitopes) are 
recognized by the immune system so that cross reactions are 
FIGURE 27.6 Typical round erythemato-violaceous lesions in 
fi xed drug eruption from piroxicam.
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better understood and patients are better informed on drugs 
to avoid in the future, how lesions fully develop and how we 
can interfere in their progression, at least in the most severe 
reactions like SJS and TEN for which no defi nitive therapy 
exists to stop their evolution and decrease mortality. 
Also, the study of hypersensitivity mechanisms induced 
by drugs, where oral rechallenge or patch testing has been a 
complementary tool to understand more pieces of this com-
plex puzzle, contributed to the understanding of pathomech-
anisms involved in nondrug related skin diseases. The 
discovery of CXCL8+ producing T-cell clones in AGEP has 
stimulated the study of their contribution in other neutrophil 
rich infl ammatory skin diseases, like psoriasis, Sweet’s syn-
drome and Beçhet’s disease, and have given immunologists 
the suggestion to consider a new type IV hypersensitivity 
reaction (IVd).5,60
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